Emisphere Wins Novartis Over
125691
Emisphere warrants close attention, although massive profits are not in the near-term cards.
559315
Novartis AG said on Wednesday that its breast cancer pill Femara is more effective than the current standard treatment tamoxifen in reducing the risk that the cancer will return to older women after surgery.
32747
Swiss pharmaceutical maker Novartis AG said Tuesday it has received U.S. approval for the hypertension drug Tekturna &#151; a potential blockbuster that has shown the ability to lower blood pressure more effectively than common treatments.
547717
BASEL, Switzerland, August 30 /PRNewswire/ -- Novartis Pharma AG has received an &quot;approvable&quot; letter from the US Food and Drug Administration (FDA) for Certican (everolimus) in combination with Neoral (ciclosporin for microemulsion) for the prevention of
448007
European regulators have endorsed a second experimental bird flu vaccine for use in humans, from Swiss drugmaker Novartis AG.
477384
Wyeth, the largest maker of hormone-replacement medicines used during menopause, won dismissal of a lawsuit in Minnesota linking its Premarin and Prempro drugs to breast cancer.
278570
Novartis AG's asthma medication Xolair effectively controlled even very severe cases of asthma, according to results of a clinical a study released on Monday.
631783
UK biotech company Cambridge Antibody Technology (CAT) has won its court fight for bigger royalties from the sale of arthritis medicine Humira.
728865
Novartis AG said on Wednesday that its  breast cancer pill Femara is more effective than the current  standard treatment tamoxifen in reducing the risk that the  cancer will return to older women after surgery.
10160
Novartis Pharmaceuticals Corp., the U.S. unit of Swiss drugmaker Novartis AG, said Thursday that at least three out of four patients given an experimental multiple sclerosis treatment were free of relapses for more than two years.
382374
The Swiss pharmaceutical giant, Novartis, on Tuesday announced an 18 percent increase in second quarter net profit to 2.02 billion dollars (1.46 billion euros) and reiterated its forecast of record profits this year.
584007
Investors reward the drugmaker for positive study results.
132487
For those that missed it last night, Biogen Idec (BIIB:Nasdaq - news - research) and Elan Pharmaceuticals (ELN:NYSE ADR - news - research) received FDA approval for their new multiple sclerosis drug, now called Tysabri (formerly known as Antegren.
295237
Novartis stays on track with its third-quarter results.
336336
BASEL, Switzerland  - Novartis AG's  fourth-quarter net profit fell 42 percent to $931 million, missing forecasts, hit by generic competition and a one-off restructuring charge, the Swiss drugmaker said on Thursday.
36316
BASEL, Switzerland  - Net profits at Novartis AG  rose by a lower-than-expected 15 percent last year as  restructuring costs weighed, the company reported on Thursday,  but the world's sixth biggest drugmaker said it expects record  sales in 2005.
423754
Consolidation in Europe's drugs   sector gathered steam on Thursday as Germany's Merck MRCG.DE   unveiled a $13.3-billion deal to buy Europe's top biotech firm   Serono SEO.VX, and Denmark's Nycomed won the drugs unit of   Altana ALTG.DE.